Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity
Open Access
- 31 May 2004
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 9 (5), 658-665
- https://doi.org/10.1016/j.ymthe.2004.02.019
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancerMolecular Therapy, 2003
- Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effectMolecular Therapy, 2003
- Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma modelMolecular Therapy, 2003
- Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanomaImmunology Letters, 2000
- Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant gliomaGene Therapy, 2000
- Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trialGene Therapy, 2000
- Systemic Antitumor Immunity in Experimental Brain Tumor Therapy Using a Multimutated, Replication-Competent Herpes Simplex VirusHuman Gene Therapy, 1999
- Herpes Simplex Virus as an in Situ Cancer Vaccine for the Induction of Specific Anti-Tumor ImmunityHuman Gene Therapy, 1999
- Immunotherapy of cancer with dendritic-cell-based vaccinesCancer Immunology, Immunotherapy, 1998
- Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.Proceedings of the National Academy of Sciences, 1993